Cornea/External Disease News

The FDA approved expanded indication language to allow the use of teprotumumab for the treatment of thyroid eye disease for any level of activity or duration, according to a press release.

Azithromycin showed equivalent efficacy to doxycycline in treating moderate to severe meibomian gland dysfunction, with reduced dosing and potentially fewer gastrointestinal adverse events, a study found.

VILAMOURA, Portugal — A high-resolution aberrometer prototype using astrophysics technology revealed unprecedented micro alterations in the wavefront phase of keratoconus eyes, which are dependent on the disease stage.

PHILADELPHIA — Symptom severity and socioeconomic factors may contribute to follow-up adherence in patients with infectious keratitis, according to a speaker.

VILAMOURA, Portugal — At the ESCRS winter meeting, Emilio Torres-Netto, MD, PhD, speaks about the advantages of PTK-assisted customized epi-on cross-linking, or PACE.

Brim Biotechnology submitted an investigational new drug application to the FDA for BRM424 for the treatment of neurotrophic keratitis, according to a press release.

It might be a completely pointless exercise to leave a large gas bubble in the eye at the end of DMEK or DSAEK surgery.

VILAMOURA, Portugal — Topography-guided corneal cross-linking for progressive keratoconus leads to stable inferior corneal Kmax flattening and superior corneal steepening, with significant improvement of vision, according to a study.

Vyznova cell therapy received regulatory approval from Japan’s Pharmaceuticals and Medical Devices Agency for the treatment of bullous keratopathy, according to a press release from Aurion Biotech.

TAMPA, Fla. — In this Healio Video Perspective from the Telling It Like It Is meeting, Neel R. Desai, MD, discusses Fortisite, a topical antibiotic compounded combination of tobramycin 1.5% and vancomycin 5% from ImprimisRx.